Jasper Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 16, 2026, reporting a net loss of $148.4 million for the nine months ended September 30, 2026.
Key Highlights
- Nine-month net loss: $148.389 million for the nine months ended September 30, 2026, compared to $66.700 million for the same period in 2025, according to the filing.
- Acquired in-process R&D charge: $129.494 million recognized in the third quarter of 2026, described in the filing as a cost related to an acquisition completed during that period.
- Revenue: $8.000 million reported for both the three and nine months ended September 30, 2026, versus zero in both comparable 2025 periods.
- Cash position: Cash and cash equivalents of $135.349 million as of September 30, 2026, up from $28.692 million at December 31, 2025.
- New preferred stock issuance: 9,555,390 shares of non-voting redeemable convertible preferred stock issued and outstanding as of September 30, 2026, carrying a carrying value of $263.502 million, with none outstanding at December 31, 2025.
- Accumulated deficit: $465.059 million as of September 30, 2026, compared to $316.670 million at December 31, 2025.
- Shares outstanding: 1,109,133 shares of voting common stock outstanding as of November 10, 2026, as reported on the cover page of the filing.
Jasper Therapeutics Reports Acquisition-Driven Charges and Preferred Stock Raise in Q3 2026
Jasper Therapeutics, Inc. (NASDAQ:JSPR), a smaller reporting company incorporated in Delaware and headquartered in Redwood City, California, filed its quarterly report covering the period ended September 30, 2026. The filing shows the company recorded a net loss of $144.455 million in the third quarter of 2026 alone, driven primarily by a $129.494 million charge for acquired in-process research and development connected to an acquisition completed during the quarter. For the full nine-month period, total costs and expenses reached $172.332 million against $8.000 million in revenue, yielding a loss from operations of $164.332 million.
According to the filing, the company completed a financing and an acquisition in the third quarter. In connection with the acquisition, 4,899,439 shares of non-voting redeemable convertible preferred stock and 173,149 shares of common stock were issued. A separate financing transaction resulted in the issuance of an additional 4,655,951 shares of non-voting redeemable convertible preferred stock, net of issuance costs of $7.411 million, raising proceeds recorded at $124.589 million. The company also declared a contingent value right (CVR) distribution of $1.900 million, which is reflected as a CVR liability on the September 30, 2026 balance sheet.
The balance sheet as of September 30, 2026 shows total assets of $147.416 million and total liabilities of $20.894 million. Total stockholders' deficit stood at $140.247 million, compared to stockholders' equity of $4.151 million at December 31, 2025. The warrant liability decreased to $3.784 million from $16.164 million at year-end 2025, with the filing attributing a $12.380 million favorable change in fair value of warrant liability for the nine-month period. Research and development expenses for the nine months were $19.276 million, down from $51.744 million in the comparable 2025 period.
What Was Disclosed
Jasper Therapeutics disclosed its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2026, including an acquisition-related in-process R&D charge of $129.494 million, a large preferred stock financing, $8.000 million in revenue, and an accumulated deficit of $465.059 million.




Please wait processing your request...